Atlanta is not the first city that comes to mind when life sciences professionals think about biotech hubs. Boston, San Francisco, San Diego, and the Research Triangle have dominated that conversation for decades. But Atlanta’s life sciences sector has been growing at a rate that the industry’s conventional geography does not reflect. Between 2020 and 2025, life sciences employment in the Atlanta metropolitan area grew by 28%, driven by a convergence of research infrastructure, public health proximity, and cost advantages that are now producing a genuine — if still emerging — biotech and medical device cluster.
Our 2025 Atlanta life sciences placements were the most we’ve made in the market in any single year: 14 senior placements spanning diagnostics, medical devices, digital health, and clinical-stage biotech. The roles ranged from VP of Regulatory Affairs at a molecular diagnostics company to Head of Quality Systems at a Class II medical device manufacturer to Chief Scientific Officer at a university spin-out. The breadth of these placements would have been impossible five years ago, when Atlanta’s life sciences demand was concentrated almost exclusively in public health and healthcare administration.
The CDC, Emory, and Georgia Tech research pipeline
Atlanta’s life sciences advantage starts with three institutional anchors that no other emerging biotech hub can replicate. The Centers for Disease Control and Prevention (CDC), headquartered in Atlanta, employs over 10,000 people in the metro area and creates a concentration of infectious disease, epidemiology, and public health expertise that has no parallel in any US city. The COVID-19 pandemic dramatically accelerated the commercialization of CDC-adjacent expertise, spawning diagnostics companies, surveillance technology startups, and contract research organizations that leverage the proximity to the nation’s public health infrastructure.
Emory University is the research engine of Atlanta’s biotech ambitions. Emory’s Winship Cancer Institute, its vaccine research center (which contributed foundational work to multiple COVID-19 vaccine programs), and its school of medicine collectively generated $831M in NIH funding in FY2024 — placing it in the top 20 nationally. Emory’s technology transfer office has produced a growing stream of spin-out companies, particularly in immunology, virology, and neuroscience, and the university’s clinical trial infrastructure supports Phase I through Phase III studies across multiple therapeutic areas.
Georgia Tech’s biomedical engineering program — ranked in the top 3 nationally — provides a pipeline of engineering talent that is particularly relevant to the medical device and diagnostics sectors. The Wallace H. Coulter Department of Biomedical Engineering, a joint venture between Georgia Tech and Emory, produces approximately 200 graduate students per year with expertise in biomechanics, neural engineering, immunoengineering, and medical imaging. This engineering talent pipeline is a genuine differentiator for Atlanta compared to biotech hubs that have deep biological sciences infrastructure but less engineering depth.
The diagnostics and medical device cluster
Atlanta’s most developed life sciences sub-sector is diagnostics and medical devices, driven by both the CDC’s diagnostic testing expertise and Georgia Tech’s engineering pipeline. Companies like Singulex (acquired by EMD Millipore), Emory-spinout Rivian Diagnostics, and several early-stage molecular diagnostics companies have established operations in the metro area. The COVID-19 pandemic created a surge of diagnostics company formation in Atlanta, and while many of those companies have since pivoted or contracted, the infrastructure — laboratory space, regulatory consultants, clinical testing partnerships — remains and is supporting a second generation of diagnostics startups focused on oncology liquid biopsy, infectious disease point-of-care testing, and multi-omic screening platforms.
The medical device segment is smaller but growing. Atlanta’s device companies are concentrated in surgical instruments, orthopedic implants, and digital health monitoring devices. The proximity to major hospital systems — Emory Healthcare, Piedmont Healthcare, WellStar, and Grady Memorial Hospital — provides clinical testing sites and KOL relationships that device companies need for design validation and early clinical evidence generation. VP-level quality and regulatory leadership at Atlanta-based device companies currently commands base salaries of $210K to $290K, with total compensation reaching $380K at well-funded companies.
Talent demand and hiring trends
The fastest-growing life sciences talent segments in Atlanta are regulatory affairs, quality systems, clinical operations, and bioinformatics. The regulatory and quality demand is driven by the diagnostics and device cluster: companies that formed during the COVID-19 pandemic under Emergency Use Authorizations are now pursuing full 510(k) or PMA clearances, which requires experienced regulatory professionals who can manage FDA submissions. The bioinformatics demand is driven by Emory’s genomics research programs and the growing number of computational biology startups that are commercializing academic research.
The talent gaps are real and specific. Atlanta does not yet have meaningful depth in pharmaceutical manufacturing leadership, CMC expertise, or large-molecule biologics development — all of which require out-of-market recruiting. The clinical development talent pool, while growing thanks to Emory’s clinical trial infrastructure, is still thin for Phase III and registration-stage trial leadership. And the commercial leadership talent pool for life sciences (VP of Commercial, Head of Market Access, Medical Affairs directors) is almost entirely absent, requiring recruitment from established pharma hubs.
Compensation: Atlanta vs. Boston and San Francisco
Atlanta’s life sciences compensation runs 25–35% below Boston and 30–40% below San Francisco Bay Area equivalents, depending on function and level. Specific benchmarks from our 2025 placements:
VP of Regulatory Affairs: Atlanta $245K–$310K base / $340K–$450K total comp, versus Boston $320K–$410K base / $480K–$650K total comp. The discount is partially offset by Georgia’s lower cost of living (housing costs run 55–65% below comparable Boston suburbs) and a state income tax that, at 5.49%, is below Massachusetts’s effective rate for high earners.
Director of Quality Systems: Atlanta $175K–$220K base / $230K–$310K total comp, versus San Francisco $230K–$290K base / $330K–$430K total comp. Quality leadership is the category where Atlanta compensation is closest to coastal equivalents, reflecting the genuine scarcity of experienced quality leaders who are willing to work outside established device hubs.
Chief Scientific Officer (clinical-stage biotech): Atlanta $290K–$380K base / $500K–$900K total comp (including equity), versus Boston $380K–$480K base / $750K–$1.4M total comp. The equity component is highly variable and depends on the company’s funding stage and valuation; Atlanta-based biotechs typically offer larger equity percentages to offset the lower cash compensation, recognizing that they are competing with established hub companies for the same scientific leadership talent.
Where Atlanta is headed
Atlanta’s life sciences trajectory over the next 3–5 years will be determined by three factors. First, whether the state of Georgia continues to invest in life sciences infrastructure: the Georgia Research Alliance and the state’s innovation fund have provided meaningful early-stage support, but the scale of investment remains well below what Massachusetts, California, and North Carolina commit to their life sciences ecosystems. Second, whether Atlanta can develop laboratory and manufacturing space at a pace that matches demand: the current inventory of Class A laboratory space in the metro area is under 2 million square feet, compared to over 40 million in Greater Boston. Third, whether Atlanta-based companies can attract and retain scientific leadership talent from established hubs — and this is where the compensation, quality of life, and institutional research partnerships will be tested most rigorously.
For life sciences professionals evaluating Atlanta, the honest assessment: this is an emerging market with genuine institutional advantages (CDC, Emory, Georgia Tech) and real cost-of-living benefits, but it is not yet a self-sustaining biotech ecosystem. The professionals who will benefit most from Atlanta’s growth are those with specific expertise in diagnostics, medical devices, or infectious disease — the sub-sectors where Atlanta has demonstrable depth. For those with therapeutic-area expertise in oncology, neuroscience, or rare disease, the established hubs remain materially stronger options. For current compensation context across life sciences markets, see our 2026 Life Sciences Compensation Report.
Strategic implications for employers
For life sciences companies considering an Atlanta presence, the strategic calculus is straightforward: Atlanta offers 25–35% lower labor costs than Boston or the Bay Area, a growing research talent pipeline from top-tier institutions, and proximity to the CDC’s public health infrastructure. The trade-offs are equally clear: thinner senior talent pools requiring out-of-market recruiting, limited laboratory and manufacturing infrastructure, and a life sciences support ecosystem (specialized law firms, regulatory consultants, CROs) that is still developing. Companies that enter Atlanta with a clear plan for which functions to build locally and which to staff through national recruiting will find the market increasingly compelling. Companies that expect to build a complete life sciences operation using only local talent will be disappointed.